Bli medlem
Bli medlem

Du är här


Infant Bacterial Therapeutics: Infant Bacterial Therapeutics enrolls First Patient in Phase 2 Clinical Trial

Infant Bacterial Therapeutics AB (publ) ("IBT") announces that the
first premature infant has been enrolled and dosed in the Company's
Phase 2 clinical trial. This Phase 2 trial is a randomized, double
blind, parallel group, dose escalation, placebo-controlled
multicenter study to investigate the safety and tolerability of
IBP-9414 administered in preterm infants.

This is the first trial in the clinical development of IBP-9414 for
the prevention of the often fatal disease necrotizing enterocolitis
which affects premature infants. The multicenter trial is being
conducted in a number of neonatal intensive care units in the US and
will enroll 120 premature infants.

More information about the clinical trial can be found on ( identifier: NCT02472769).

Staffan Strömberg, Chief Executive Officer of IBT, comments, "We are
very excited to have started the study and to now have the first baby
included. This is an important milestone in our development of this
potentially life-saving new drug."

For additional information please contact

Staffan Strömberg, CEO, phone: +46 8 410 145 55

Peter Rothschild, Chairman of the Board, phone: +46 8 410 145 55

Infant Bacterial Therapeutics AB

Bryggargatan 10

111 21 Stockholm, Sweden

Phone: +46 8 410 145 55

Infant Bacterial Therapeutics AB ("IBT") is a pharmaceutical company
based in Stockholm that develops drugs that meet the needs of the
premature infants. IBT's current focus is on clinical development of
IBP-9414, a drug candidate containing Lactobacillus reuteri, in the
prevention of necrotizing enterocolitis ("NEC"), a fatal disease that
affects premature infants. IBT is listed on Nasdaq First North with
Erik Penser Bankaktiebolag as Certified adviser.


Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.